Tima Davidson

Tima Davidson

Auto-generated profile, based on publicly available information

Tima Davidson

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
YEYael Md Eshet
Yael Md Eshet
NTNoam Tau
Noam Tau
KLKeren Levanon
Keren Levanon
RBRinat Bernstein-Molho
Rinat Bernstein-Molho
OGOfer Globus
Ofer Globus
LDLiran Domachevsky
Liran Domachevsky
Purpose: 68Ga–fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. Methods: We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. Results: Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2–4 follow-up scans). We found a strong correlation between 68Ga-FAPI tumor volume and blood biomarkers (r = 0.7, P < 0.01), but weak correlation between CT and 68Ga-FAPI maximal intensity projection–based qualitative response assessment. Conclusions: We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68Ga-FAPI tumor volume. 68Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.

1 January 2009 in World Journal of Gastroenterology
Verified
Journal Article
Open access
NSNadav Sahar
Nadav Sahar
GSGinette Schiby
Ginette Schiby
TDTima Davidson
Tima Davidson
AKAbraham Kneller
Abraham Kneller
SASara Apter
Sara Apter
ZFZvi Farfel
Zvi Farfel
Hairy cell leukemia presenting as multiple discrete hepatic lesions

1 August 2016 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
SBSimona Ben-Haim
Simona Ben-Haim
JGJenny Garkaby
Jenny Garkaby
NPNatalia Primashvili
Natalia Primashvili
EGElinor Goshen
Elinor Goshen
RSRonnie Shapira
Ronnie Shapira
RERon Epelbaum
Ron Epelbaum
Objectives Merkel cell carcinoma (MCC) is a rare aggressive skin tumor associated with a high mortality rate. The present study evaluated the role of fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) in subsequent management of patients with MCC. Methods A total of 101 consecutive 18F-FDG PET/CT studies of 46 patients with MCC (28 men, 68±15.4 years) were retrospectively evaluated and the role in clinical care was documented. Results There were 40 positive studies (40%) in 28 patients (61%); of these, 33 studies (33%) in 27 patients (59%) showed metastatic disease. Fifty-two PET/CT studies (51%) in 23/46 (50%) patients were negative. Fifty-three studies (52%) were performed for staging or restaging in 41 patients, 29 scans (29%) were performed for routine follow-up in 10 patients, nine studies were carried out for suspected recurrent disease in eight patients, and 10 studies were carried out for assessment of response to therapy in seven patients. On the basis of PET/CT results, there was a change in disease stage in 12 studies in 12 patients (26%) and further change in the management of seven patients (15%). Overall, 2/29 routine follow-up studies were positive with further impact on management in one patient. Conclusion 18F-FDG PET-CT altered the stage of one of four patients and changed the management of one of seven MCC patients. In the majority of patients, a negative 18F-FDG PET-CT study excluded active MCC with a high degree of confidence. PET-CT contributed toward patient management when performed for staging and restaging, monitoring response to treatment, and suspected recurrent disease, but not in the routine follow-up of asymptomatic patients with MCC.

10 June 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
RLRaya Leibowitz
Raya Leibowitz
TDTima Davidson
Tima Davidson
MGMoran Gadot
Moran Gadot
MAMargalit Aharon
Margalit Aharon
AMAvraham Malki
Avraham Malki
RBRaanan Berger
Raanan Berger
Background: Prostate cancer is a common malignancy of the elderly, and with the aging of the population, the need is growing for therapies suitable for this age group. Lutetium-177–prostate-specific membrane antigen (Lu-PSMA), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen, enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). In a recent single-arm phase II trial and a subsequent expansion cohort, a prostate-specific antigen (PSA) decline of ≥50% was observed in approximately 60% of patients receiving Lu-PSMA. Taking into account the specific challenges and potential toxicities of Lu-PSMA administration in elderly men, we sought to retrospectively analyze the safety and activity of Lu-PSMA in men aged older than 75 years with mCRPC. Patients and Methods: The electronic medical records of 24 patients aged older than 75 years treated with Lu-PSMA “off-trial” were reviewed, and clinical data were extracted. Clinical endpoints were toxicity and activity, defined as a PSA decline ≥50%. Descriptive statistics were performed using Excel. Results: The median age at treatment start was 81.7 years (range 75.1–91.9). The median number of previous treatment lines was four. The number of treatment cycles ranged from one to four; the mean administered radioactivity was 6 GBq per cycle. Treatment was generally tolerable; side effects included fatigue (n = 8, 33%), anemia (n = 7, 29%), thrombocytopenia (n = 5, 21%), and anorexia/nausea (n = 3, 13%). Clinical benefit was observed in 12 of 22 patients (54%); PSA decline above 50% was observed in 11 patients (48%) and was associated with significantly longer overall survival. Conclusion: Our results indicate that Lu-PSMA is safe and active in elderly patients with mCRPC. Implications for Practice: Lutetium-177–prostate-specific membrane antigen (Lu-PSMA), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen, enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). The recently published single-arm phase II trial with Lu-PSMA, describing its safety and activity, did not include patients aged older than 75 years. In this study, Lu-PSMA activity was retrospectively analyzed in patients aged older than 75 years and results indicate that treatment was tolerable and similarly active in this age group, with no new emerging safety signals. Despite the small cohort size, this analysis suggests that Lu-PSMA can serve as an advanced palliative treatment line in mCRPC in elderly patients.

1 May 2018 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
ESEinat Slonimsky
Einat Slonimsky
JKJacob Korach
Jacob Korach
TPTamar Perri
Tamar Perri
TDTima Davidson
Tima Davidson
SASara Apter
Sara Apter
YIYael Inbar
Yael Inbar
Objective: The aim of the study was to evaluate the radiological characteristics of gynecological lymphoproliferative disease (LPD) and specific imaging features that may suggest the diagnosis. Methods: Two readers conducted a retrospective evaluation of imaging studies of 13 female patients presenting with a gynecological LPD. A literature review was also performed. Results: Of the 13 evaluated women, 9 had ovarian involvement, 3 had cervical involvement, and 1 had uterine involvement. The most common lesion characteristics were homogenous masses (11), with mild contrast enhancement (9), followed by soft-tissue necrosis (4), prominent blood vessels displaced by the lesions (4), linear arrangement of cysts at the periphery of the ovaries (3), and “touching” ovaries in all cases of bilateral ovarian involvement. Conclusions: A solid large homogeneous mass with mild contrast enhancement should alert the radiologist to the possibility of the differential diagnosis of LPD. Radiologists should be “the gatekeepers” by raising this possibility to avoid unnecessary surgery and enable appropriate treatment.

20 October 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
JSJennifer Ben Shimol
Jennifer Ben Shimol
YGYuli Guzman-Prado
Yuli Guzman-Prado
MKMaria Karlinskaya
Maria Karlinskaya
TDTima Davidson
Tima Davidson